Ingrid Pamela Morales-Cedillo

Ingrid Pamela Morales-Cedillo

Auto-generated profile, based on publicly available information

Ingrid Pamela Morales-Cedillo

Pharmacogenetics Department, Subdirectorate of Clinical Research, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101. Col. San Lorenzo, Huipulco. CP 14370, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Complex Psychiatry
Verified
Journal Article
Open access
PDF file
BCBeatriz Camarena
Beatriz Camarena
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
MBMark Baker
Mark Baker
CBClaudia Becerra-Palars
Claudia Becerra-Palars
LCLori B. Chibnik
Lori B. Chibnik
KKKarestan C. Koenen
Karestan C. Koenen
No large-scale genome-wide association studies (GWASs) of psychosis have been conducted in Mexico or Latin America to date. Schizophrenia and bipolar disorder in particular have been found to be highly heritable and genetically influenced. However, understanding of the biological basis of psychosis in Latin American populations is limited as previous genomic studies have almost exclusively relied on participants of Northern European ancestry. With the goal of expanding knowledge on the genomic basis of psychotic disorders within the Mexican population, the National Institute of Psychiatry Ramón de la Fuente Muñiz (INPRFM), the Harvard T.H. Chan School of Public Health, and the Broad Institute’s Stanley Center for Psychiatric Research launched the Neuropsychiatric Genetics Research of Psychosis in Mexican Populations (NeuroMex) project to collect and analyze case-control psychosis samples from 5 states across Mexico. This article describes the planned sample collection and GWAS protocol for the NeuroMex study. The 4-year study will span from April 2018 to 2022 and aims to recruit 9,208 participants: 4,604 cases and 4,604 controls. Study sites across Mexico were selected to ensure collected samples capture the genomic diversity within the Mexican population. Blood samples and phenotypic data will be collected during the participant interview process and will contribute to the development of a local biobank in Mexico. DNA extraction will be done locally and genetic analysis will take place at the Broad Institute in Cambridge, MA. We will collect extensive phenotypic information using several clinical scales. All study materials including phenotypic instruments utilized are openly available in Spanish and English. The described study represents a long-term collaboration of a number of institutions from across Mexico and the Boston area, including clinical psychiatrists, clinical researchers, computational biologists, and managers at the 3 collaborating institutions. The development of relevant data management, quality assurance, and analysis plans are the primary considerations in this protocol article. Extensive management and analysis processes were developed for both the phenotypic and genetic data collected. Capacity building, partnerships, and training between and among the collaborating institutions are intrinsic components to this study and its long-term success.

1 May 2020 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
ARAlejandra Monserrat Rodríguez-Ramírez
Alejandra Monserrat Rodríguez-Ramírez
FMFátima Meza-Urzúa
Fátima Meza-Urzúa
VCValente Cedillo-Ríos
Valente Cedillo-Ríos
CBClaudia Becerra-Palars
Claudia Becerra-Palars
JJJoanna Jimenez-Pavon
Joanna Jimenez-Pavon
BCBeatriz Camarena
Beatriz Camarena
Purpose: Bipolar disorder (BD) is a condition associated with structural alterations in the prefrontal cortex (PFC); some genetic variants and mood stabilizer medications like lithium or valproate are associated with these changes. CACNA1C is a gene involved in BD pathology and brain function; carriers of the A allele of rs1006737 are reported to have increased risk for BD and increased cortical thickness (CT) in the PFC compared to non-carriers. Lithium is also associated with increased CT in the PFC of BD subjects compared to the ones on valproate. The influence of these treatments and gene variants over the PFC structure of Mexican subjects has not been explored. Therefore, we evaluate the effects of mood stabilizers and risk A allele of CACNA1C rs1006737 on the prefrontal cortical thickness of Mexican BD patients treated with lithium or valproate. Patients and Methods: A cross-sectional study of 40 BD type I euthymic adult outpatients (20 treated with lithium and 20 with valproate) who underwent a 3T T1-weighted 3D brain scan and genotyping for CACNA1C risk allele rs1006737 was conducted. We performed a cortical thickness analysis of the dorsolateral and orbitofrontal regions of the prefrontal cortex with BrainVoyager 20.6. The effects of treatment and gene variants were analyzed with a two-way multivariate analysis of covariance. Results: There was no association of CACNA1C risk allele rs1006737 with CT measures of both PFCs nor significant interaction between the genetic variant and treatment. Mood stabilizers reported the main effect on the CT measures of the right PFC of our sample. Patients on treatment with lithium showed higher mean CT on the right orbitofrontal cortex. Conclusion: We did not find any association between the prefrontal CT and CACNA1C risk A allele rs1006737 in BD Mexican patients treated with lithium or valproate. Our results suggest that mood stabilizers had the main effect in the CT of the right PFC.

14 August 2025 in Pharmacological Reports
Verified
Journal Article
Closed access
BCBeatriz Camarena
Beatriz Camarena
MJMarco Antonio Sanabrais Jiménez
Marco Antonio Sanabrais Jiménez
Carlo Esteban Sotelo RamirezCarlo Esteban Sotelo Ramirez
Carlo Esteban Sotelo Ramirez
JJJoanna Jimenez-Pavon
Joanna Jimenez-Pavon
PMPamela Morales-Cedillo
Pamela Morales-Cedillo
CBClaudia Becerra-Palars
Claudia Becerra-Palars